
Harvard Bioscience (HBIO) Stock Forecast & Price Target
Harvard Bioscience (HBIO) Analyst Ratings
Bulls say
Harvard Bioscience is attractive on fundamentals because 2Q revenue of $22.7 million beat expectations, and full-year 2026 revenue growth guidance was raised to 3-5% while Adjusted EBITDA growth of 6-10% was reaffirmed. Its new product innovation pipeline is gaining traction, with NPI contributing about 11% of 2Q revenue and targeted to reach 15-20% in 2027, supported by strong sales in the Americas up 13% and China up 29%. In addition, Project Viking is on track to generate $3 million of cost savings in 2027 and $4 million in 2028, with restructuring substantially complete by 1Q 2027, supporting margin expansion and balance sheet delevering.
Bears say
Harvard Bioscience is facing a weaker fundamental setup because 3Q results only met expectations while management lowered the 2026 EBITDA target, citing a less favorable mix toward lower-margin CMT products and more distribution and China revenue. Although biopharma demand and NPI platforms such as SoHo, MeshMEA, and BTX support longer-term innovation, the investment case is constrained by a 12% WACC, a 49% debt-to-capital ratio, and operating and EBITDA margins that do not justify multiple expansion. The outlook is further pressured by restructuring and consolidation risks from Project Viking, heightened FDA and regulatory uncertainty, exposure to NIH and other funding cycles, and currency and competitive pressures that could disrupt execution.
This aggregate rating is based on analysts' research of Harvard Bioscience and is not a guaranteed prediction by Public.com or investment advice.
Harvard Bioscience (HBIO) Analyst Forecast & Price Prediction
Start investing in Harvard Bioscience (HBIO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Harvard Bioscience (HBIO) Forecast
Harvard Bioscience (HBIO) Analyst Forecast & Price Prediction
Start investing in Harvard Bioscience (HBIO)
Order type
Buy in
Order amount
Est. shares
0 shares